Afriplex Strengthens Its Position in the US Market After Successful SupplySide Global 2026 Exhibition
South African botanical innovation draws strong US interest as Afriplex builds new partnerships and opens doors for
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
South African botanical innovation draws strong US interest as Afriplex builds new partnerships and opens doors for local pharmaceutical and healthcare firms
PAARL, WESTERN CAPE, SOUTH AFRICA, November 17, 2026 /EINPresswire.com/ — South African pharmaceutical and botanical ingredient manufacturer Afriplex has reported a highly successful participation at SupplySide Global 2026 in Las Vegas, United States, marking an important milestone in the company’s strategy to expand its international presence and establish a stronger commercial foothold in the world’s largest consumer healthcare market.
The exhibition, a leading gathering of ingredient suppliers, manufacturers, formulators and healthcare industry stakeholders, provided Afriplex with an international platform to showcase its portfolio of innovative African botanical ingredients.
Of particular significance was the exceptional interest generated by two of Afriplex’s flagship products: Kannaspectrum™, its standardised Sceletium tortuosum extract, and Pelargonium S70™, its pharmaceutical-grade Pelargonium sidoides extract developed for applications in respiratory healthcare.
Beyond the considerable commercial interest in these ingredients, Afriplex established new strategic relationships with international industry participants, creating opportunities for future distribution, product development and market collaboration. These developments strengthen the company’s ability to connect South African pharmaceutical, complementary medicine and healthcare manufacturers with opportunities and partners in the United States.
Director’s perspective
“Our participation at SupplySide Global confirmed that there is significant appetite in the United States for differentiated, scientifically developed ingredients originating in Africa. The response to Kannaspectrum and Pelargonium S70 was particularly encouraging, but the greater opportunity extends beyond Afriplex’s own products,” said Donnie Malherbe, Director of Afriplex.
By establishing new relationships with US ingredient companies, manufacturers and commercial partners, we are creating a bridge between South African innovation and the American market. Our objective is not only to grow Afriplex internationally, but also to unlock opportunities for our South African customers by giving them access to market intelligence, expertise and commercial networks that would otherwise be difficult to reach.”
Global ingredient trends: Functionality, natural alternatives and targeted innovation
SupplySide Global 2026 highlighted the continuing transformation of the international ingredient industry, driven by changing consumer expectations, scientific advances and the growing importance of functionality in healthcare and nutrition products.
Where ingredient selection was historically often driven by price, availability and established formulation practices, manufacturers increasingly seek differentiated ingredients offering clearly defined functionality, scientific substantiation and meaningful benefits for specific consumer needs.
This evolution is evident in interest in natural alternatives, plant-derived active ingredients and innovative formulations combining traditional botanical knowledge with modern scientific development. Functional ingredients are increasingly considered for products addressing stress management, cognitive performance, sleep, healthy ageing, metabolic health, immune support and general wellbeing.
The exhibition reinforced the importance of tailoring ingredients to specific applications and market requirements. Manufacturers seek defined active constituents, consistent quality, documented specifications and characteristics supporting formulation into particular dosage forms. This places greater emphasis on ingredient standardisation, stability, regulatory documentation and suppliers’ ability to collaborate during product development.
For Afriplex, these developments align with its long-term strategy of transforming African botanical resources into scientifically developed, commercially relevant ingredients. Rather than competing exclusively in commodity extracts, the company is focusing on differentiated ingredients combining African botanical heritage with modern pharmaceutical manufacturing standards.
Afriplex’s specialised botanical ingredients draw international attention
Among the highlights of Afriplex’s participation at SupplySide Global was the exceptional interest in its specialised South African botanical ingredients. Two products in particular, Kannaspectrum™, derived from Sceletium tortuosum, and Pelargonium S70™, its Pelargonium sidoides active pharmaceutical ingredient, demonstrated how indigenous botanical resources can be developed into differentiated solutions for international healthcare markets.
Although intended for different applications, both extracts reflect the same underlying shift in the global ingredient industry: manufacturers are seeking natural-origin ingredients with clearly defined functionality, reliable specifications and the technical support necessary to develop commercially relevant products. The response to Afriplex’s portfolio suggested that African botanicals can compete on more than their origin or traditional reputation.
Kannaspectrum1™, standardised to 1% total alkaloids, attracted considerable attention from companies exploring the expanding mood, stress and cognitive wellness categories. Sceletium has a history of traditional use in Southern Africa, while its characteristic alkaloids, including mesembrine and mesembrenone, have become subjects of scientific and commercial interest. For prospective US customers, consistent standardisation and the potential to incorporate the extract into targeted formulations are central considerations.
Alongside this interest, Pelargonium S70™ drew enquiries relating to respiratory healthcare applications. Developed from Pelargonium sidoides, it illustrates Afriplex’s ability to apply pharmaceutical manufacturing expertise to African medicinal plants. Potential customers in this field place particular emphasis on ingredient consistency, analytical characterisation, quality assurance and the documentation needed to support product development.
Together, these products also demonstrate the breadth of Afriplex’s offering: from functional botanical ingredients intended for innovative consumer wellness products to active pharmaceutical ingredients developed for more demanding technical applications. Both require an understanding of market-specific formulation needs rather than a one-size-fits-all approach to botanical extraction.
Afriplex’s vertically integrated supply chain strengthens this proposition. Its capabilities encompass botanical raw material sourcing, extraction, standardisation, analytical testing and formulation development. In the case of Sceletium, relevant bioprospecting arrangements and permits support the responsible commercial development of an indigenous South African resource.
Discussions at the exhibition also provided valuable insight into the expectations of American buyers, including formulation compatibility, scalability, regulatory documentation and the ability to provide a dependable long-term supply. These requirements are particularly important when introducing relatively unfamiliar African ingredients into established international product portfolios.
For Afriplex, the interest in Kannaspectrum™ and Pelargonium S70™ was therefore significant not simply as a response to two individual products, but as evidence of the broader potential for specialised African botanical ingredients. Their development demonstrates how South African expertise can add value locally, moving beyond raw-material exports towards standardised, technically supported ingredients for international manufacturers.
Commercial opportunities will depend on the applicable US regulatory pathways and on converting exhibition discussions into sustained customer relationships. Nevertheless, the strength and range of enquiries reinforced Afriplex’s confidence that its specialised ingredient portfolio addresses genuine areas of international market interest.
A largely untapped opportunity for African botanical ingredients
One of the most significant conclusions emerging from Afriplex’s participation is the scale of opportunity for innovative African botanical ingredients in the United States. Despite the sophistication and size of the American health and nutrition industry, numerous African botanical resources remain relatively unfamiliar to US manufacturers and consumers.
While botanical ingredients originating from Asia, Europe and the Americas have achieved substantial international commercial penetration, many African species with potentially valuable functional properties have yet to achieve comparable recognition.
Afriplex sees an opportunity to establish a stronger presence for African ingredients in international formulation and product development programmes. Its strategy is not simply to export existing products into new territories, but to identify market needs where African botanical resources can offer meaningful differentiation.
This requires understanding functionality sought by manufacturers, developing ingredients that meet technical specifications and addressing regulatory and commercial requirements. Success in the United States also demands sustained engagement. Credibility with distributors, pharmaceutical companies, contract manufacturers and developers is built gradually on technical competence, consistent quality and dependable commercial relationships.
By engaging directly with potential customers and partners, Afriplex is working to overcome geographical and commercial barriers that have historically limited the international reach of many African botanical ingredients.
Strategic partnerships create new opportunities
An especially encouraging outcome was the establishment of new relationships with international companies across ingredient supply, formulation and manufacturing. These connections provide opportunities to explore distribution arrangements, collaborative product development and partnerships aimed at strengthening Afriplex’s US presence.
For a South African manufacturer, building a sustainable US presence requires more than technically competitive products. Established distribution networks, local market knowledge, regulatory expertise and relationships with manufacturers can significantly influence market entry.
Afriplex is therefore pursuing a partnership-driven approach that combines its botanical and pharmaceutical manufacturing expertise with the commercial capabilities of international participants. These relationships can help identify emerging opportunities, respond to market requirements and introduce differentiated African products to a broader customer base.
Importantly, their potential benefits are not limited to Afriplex’s own ingredient portfolio.
Creating a conduit between South African manufacturers and the US market
For South African pharmaceutical and healthcare companies, Afriplex’s growing international network represents an additional avenue to explore the US market through an established local manufacturing and technical partner.
Many South African companies possess valuable product development expertise, established brands and innovative formulations, yet face challenges in international expansion. These include unfamiliar regulatory requirements, limited overseas distribution networks, difficulty identifying commercial partners and the cost of developing an international presence independently.
By building relationships with US ingredient companies, distributors, formulators and manufacturing organisations, Afriplex is positioning itself as a commercial and technical conduit between the South African healthcare industry and international markets.
This creates opportunities for collaboration in ingredient sourcing, formulation development, contract manufacturing, product adaptation and introductions to overseas partners. South African companies developing products for international markets may benefit from Afriplex’s understanding of US ingredient preferences, formulation trends and market expectations.
Similarly, companies seeking innovative botanical ingredients for existing portfolios may gain access to specialised ingredients and international development partners through Afriplex’s network. These opportunities complement Afriplex’s established contract development and manufacturing capabilities, supporting customers across stages of product development.
Rather than viewing international expansion exclusively as a means of increasing export sales, Afriplex sees it as an opportunity to strengthen the broader South African pharmaceutical and healthcare value chain.
Vertical integration provides a competitive advantage
A key differentiator is Afriplex’s vertically integrated operating model. The company combines botanical raw material supply arrangements with extraction, formulation development, analytical testing, stability studies and finished-product manufacturing capabilities.
This structure provides greater control over critical aspects of product quality and supports closer collaboration between ingredient development and finished-product formulation, increasingly important as customers seek ingredients tailored to specific applications.
Afriplex operates within a pharmaceutical quality framework, including SAHPRA-regulated manufacturing capabilities, and maintains food safety systems relevant to functional ingredients and nutraceutical activities. Its technical infrastructure includes analytical and microbiological testing, product characterisation, quality control and stability assessment.
These capabilities matter in an international market where buyers increasingly require comprehensive technical documentation and confidence in supply chain reliability. The combination of ingredient development and pharmaceutical manufacturing expertise also enables more complex or specialised formulations.
From natural ingredients to market-specific solutions
Another important message from SupplySide Global is that future ingredient innovation will increasingly depend on responding to specific market needs. Natural origin alone is no longer sufficient to guarantee commercial success.
Manufacturers want ingredients suitable for commercially viable products, with intended functionality, shelf-life stability and consumer appeal. Developers must consider active compound concentration, solubility, sensory characteristics, processing stability and compatibility with dosage forms.
Consumer preferences also vary between markets. An ingredient developed for a conventional pharmaceutical dosage form may require a different approach for a functional beverage, gummy, powder or other convenient format.
Afriplex’s combination of extraction expertise and finished-product development allows the company to address these factors early, working with customers to adapt botanical ingredients to particular applications rather than offering fixed specifications without regard to intended use.
For South African companies, these developments underline the value of access to international formulation trends and emerging ingredient technologies. Afriplex intends to use intelligence and relationships gained internationally to help customers respond to changing requirements.
Building international value from African innovation
Afriplex’s successful participation at SupplySide Global 2026 represents another step towards establishing African botanical innovation as a recognised contributor to international pharmaceutical and functional ingredient markets.
The strong interest in Kannaspectrum™ and Pelargonium S70™ demonstrates the potential appeal of differentiated African ingredients supported by scientific, manufacturing and commercial capabilities. Equally important, new relationships established during the exhibition provide a platform for continued international collaboration.
The objective is not simply greater visibility for Afriplex products, but sustainable commercial channels through which African innovation can reach international manufacturers. This has important implications for South African pharmaceutical and healthcare companies seeking a greater role in global markets.
By strengthening its US presence, Afriplex is creating opportunities to connect local manufacturing expertise with international market demand, ingredient innovation and commercial partnerships.
South Africa has botanical resources, scientific expertise and manufacturing capabilities with which to compete internationally. The opportunity lies in translating these strengths into commercially successful products and enduring global partnerships. Afriplex intends to remain at the forefront of that development, connecting African botanical innovation with global opportunities while creating additional value for its South African customers.
About Afriplex
Afriplex is a South African pharmaceutical and botanical ingredient manufacturer based in Paarl, Western Cape. The company specialises in botanical extraction, active pharmaceutical ingredients, contract development and manufacturing, and scientific and technical services.
With vertically integrated capabilities encompassing raw material sourcing, extraction, formulation development, quality control, stability testing and finished-product manufacturing, Afriplex serves pharmaceutical, nutraceutical and functional ingredient customers.
Website: www.afriplex.com
Daniel Nel
Clonelabs PTY LTD
+27 21 344 4953
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery
